Emerging Infectious Disease Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Application (Laboratory Testing and Point of Care Testing), By Technology (Polymerase chain reaction, Immunodiagnostics, Isothermal Nucleic Acid Amplification Technology (INAAT), Next-Generation Sequencing (NGS), and Others), By Type of Infection (Bacterial, Viral, Fungal, and Others), By Disease Type (Respiratory Infections, Gastrointestinal Infections, Sexually Transmitted Infections (STIs), and Others), By End user (Hospitals & Clinics, Diagnostic laboratories, and Others), By Region & Competition, 2021-2031F
The Global Emerging Infectious Disease Diagnostics Market is projected to expand from USD 16.70 Billion in 2025 to USD 27.41 Billion by 2031, achieving a CAGR of 8.61%. This sector comprises specialized assays and platforms engineered to detect pathogens that have recently appeared or are experiencing rapid increases in incidence and geographic reach. The market is largely driven by the rising prevalence of zoonotic and vector-borne diseases, which necessitates the development of robust surveillance capabilities. Additionally, significant government funding dedicated to biodefense infrastructure and pandemic preparedness programs acts as a vital economic catalyst, encouraging continuous product innovation and deployment.
Despite these drivers, the industry encounters major obstacles regarding the high costs and complex regulatory requirements involved in validating tests for novel pathogens during active outbreaks. These financial and operational hurdles can impede the timely commercialization of essential testing kits when they are most critical. According to the World Health Organization, more than 14.6 million dengue cases were reported worldwide in 2024, underscoring the urgent need for accessible and scalable diagnostic solutions to effectively manage such widespread public health threats.
Market Driver
The rising frequency of emerging and re-emerging infectious outbreaks serves as a primary catalyst for the market, requiring the rapid implementation of specialized testing solutions to mitigate cross-border threats. As pathogens extend their geographic footprint, public health agencies are increasingly procuring molecular and immunoassay platforms to facilitate early detection and contact tracing. This surge in viral activity drives immediate demand for high-throughput screening kits and point-of-care devices designed to function in resource-limited environments. For example, according to the Africa Centres for Disease Control and Prevention, a total of 21,466 potential Mpox cases were reported across the continent by August 2024, emphasizing the critical need for accessible diagnostic infrastructure to control escalating transmission rates.
Simultaneously, increased government funding for disease surveillance is significantly strengthening the sector's capacity for innovation. Federal agencies are directing substantial capital toward developing next-generation medical countermeasures, thereby reducing the risks associated with the complex validation process for tests targeting novel agents. These investments allow private enterprises to enhance their research capabilities and maintain readiness for future biological threats. A prominent example of this support occurred in January 2024, when ATCC received a five-year, $87 million award from the Biomedical Advanced Research and Development Authority to advance new diagnostic tools. This financial backing ensures market stability; according to Roche, in October 2024, its Diagnostics division reported sales of CHF 10.7 billion for the first nine months of the year, reflecting the enduring value of infectious disease testing portfolios.
Market Challenge
The substantial costs and regulatory intricacies involved in validating tests for novel pathogens present significant barriers to market expansion. Manufacturers encounter considerable financial risk when developing assays for sporadic outbreaks, as demand may decline before regulatory approval is fully finalized. This economic uncertainty deters sustained investment in research and development for emerging threats, prompting companies to prioritize established markets with predictable revenue streams over volatile infectious disease segments. Consequently, the rigorous validation procedures required by health authorities prolong the time it takes to bring products to market, often leaving healthcare systems without necessary tools during the initial stages of infection waves.
This regulatory burden directly affects product availability and disrupts portfolio continuity. Smaller developers are particularly susceptible to these resource demands, which can compel them to consolidate or withdraw products entirely. According to MedTech Europe, approximately 17 percent of in vitro diagnostic tests were expected to be discontinued in 2024 due to the extensive costs and resources required to comply with new regulatory standards. This reduction in the availability of approved tests limits the overall growth potential of the diagnostics sector.
Market Trends
The expansion of Syndromic Multiplex Diagnostic Panels is revolutionizing clinical management by facilitating the simultaneous detection of multiple pathogens from a single sample, thereby addressing the difficulty of distinguishing symptoms in respiratory and gastrointestinal infections. This methodology improves operational efficiency in healthcare facilities by replacing sequential testing with comprehensive panels that provide rapid, actionable results for co-circulating viruses. The market viability of this trend is highlighted by the strong performance of specialized syndromic platforms; according to bioM?rieux?s 'First-Half 2024 Results' in September 2024, sales of BIOFIRE respiratory panels rose by 17 percent in the second quarter, driven by the solution?s competitiveness and the utilization of the existing installed base.
In parallel, the acceleration of decentralized and Point-of-Care (POC) testing is reshaping the diagnostic landscape by moving complex molecular testing capabilities from reference laboratories to near-patient settings, such as urgent care clinics and physician offices. This shift is fueled by the need to shorten turnaround times for treatment initiation, enabling providers to make immediate clinical decisions without the logistical delays associated with central lab transport. Industry leaders are capitalizing on this demand by broadening their portfolios of compact, automated systems. According to Danaher?s 'Third Quarter 2024 Results' in October 2024, Cepheid?s diagnostics revenue for respiratory products reached $425 million for the quarter, underscoring the sustained market reliance on rapid, decentralized molecular testing solutions.
Key Market Players
%li%BioMerieux SA
%li%Bio-Rad Laboratories, Inc.
%li%Becton, Dickinson and Company
%li%Agilent Technologies, Inc.
%li%Abbott Laboratories, Inc.
%li%Thermo Fisher Scientific, Inc.
%li%Roche Diagnostics Corporation
%li%DiaSorin SpA
%li%F. Hoffmann-La Roche Ltd.
%li%Danaher Corporation
Report Scope
In this report, the Global Emerging Infectious Disease Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
%li%Emerging Infectious Disease Diagnostics Market, By Application
%li%%li%Laboratory Testing
%li%%li%Point of Care Testing
%li%Emerging Infectious Disease Diagnostics Market, By Technology
%li%%li%Polymerase chain reaction
%li%%li%Immunodiagnostics
%li%%li%Isothermal Nucleic Acid Amplification Technology (INAAT)
%li%%li%Next-Generation Sequencing (NGS)
%li%%li%Others
%li%Emerging Infectious Disease Diagnostics Market, By Type of Infection
%li%%li%Bacterial
%li%%li%Viral
%li%%li%Fungal
%li%%li%Others
%li%Emerging Infectious Disease Diagnostics Market, By Disease Type
%li%%li%Respiratory Infections
%li%%li%Gastrointestinal Infections
%li%%li%Sexually Transmitted Infections (STIs)
%li%%li%Others
%li%Emerging Infectious Disease Diagnostics Market, By End user
%li%%li%Hospitals & Clinics
%li%%li%Diagnostic laboratories
%li%%li%Others
%li%Emerging Infectious Disease Diagnostics Market, By Region
%li%%li%North America
%li%%li%%li%United States
%li%%li%%li%Canada
%li%%li%%li%Mexico
%li%%li%Europe
%li%%li%%li%France
%li%%li%%li%United Kingdom
%li%%li%%li%Italy
%li%%li%%li%Germany
%li%%li%%li%Spain
%li%%li%Asia Pacific
%li%%li%%li%China
%li%%li%%li%India
%li%%li%%li%Japan
%li%%li%%li%Australia
%li%%li%%li%South Korea
%li%%li%South America
%li%%li%%li%Brazil
%li%%li%%li%Argentina
%li%%li%%li%Colombia
%li%%li%Middle East & Africa
%li%%li%%li%South Africa
%li%%li%%li%Saudi Arabia
%li%%li%%li%UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Emerging Infectious Disease Diagnostics Market.
Available Customizations:
Global Emerging Infectious Disease Diagnostics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
%li%Detailed analysis and profiling of additional market players (up to five).
Despite these drivers, the industry encounters major obstacles regarding the high costs and complex regulatory requirements involved in validating tests for novel pathogens during active outbreaks. These financial and operational hurdles can impede the timely commercialization of essential testing kits when they are most critical. According to the World Health Organization, more than 14.6 million dengue cases were reported worldwide in 2024, underscoring the urgent need for accessible and scalable diagnostic solutions to effectively manage such widespread public health threats.
Market Driver
The rising frequency of emerging and re-emerging infectious outbreaks serves as a primary catalyst for the market, requiring the rapid implementation of specialized testing solutions to mitigate cross-border threats. As pathogens extend their geographic footprint, public health agencies are increasingly procuring molecular and immunoassay platforms to facilitate early detection and contact tracing. This surge in viral activity drives immediate demand for high-throughput screening kits and point-of-care devices designed to function in resource-limited environments. For example, according to the Africa Centres for Disease Control and Prevention, a total of 21,466 potential Mpox cases were reported across the continent by August 2024, emphasizing the critical need for accessible diagnostic infrastructure to control escalating transmission rates.
Simultaneously, increased government funding for disease surveillance is significantly strengthening the sector's capacity for innovation. Federal agencies are directing substantial capital toward developing next-generation medical countermeasures, thereby reducing the risks associated with the complex validation process for tests targeting novel agents. These investments allow private enterprises to enhance their research capabilities and maintain readiness for future biological threats. A prominent example of this support occurred in January 2024, when ATCC received a five-year, $87 million award from the Biomedical Advanced Research and Development Authority to advance new diagnostic tools. This financial backing ensures market stability; according to Roche, in October 2024, its Diagnostics division reported sales of CHF 10.7 billion for the first nine months of the year, reflecting the enduring value of infectious disease testing portfolios.
Market Challenge
The substantial costs and regulatory intricacies involved in validating tests for novel pathogens present significant barriers to market expansion. Manufacturers encounter considerable financial risk when developing assays for sporadic outbreaks, as demand may decline before regulatory approval is fully finalized. This economic uncertainty deters sustained investment in research and development for emerging threats, prompting companies to prioritize established markets with predictable revenue streams over volatile infectious disease segments. Consequently, the rigorous validation procedures required by health authorities prolong the time it takes to bring products to market, often leaving healthcare systems without necessary tools during the initial stages of infection waves.
This regulatory burden directly affects product availability and disrupts portfolio continuity. Smaller developers are particularly susceptible to these resource demands, which can compel them to consolidate or withdraw products entirely. According to MedTech Europe, approximately 17 percent of in vitro diagnostic tests were expected to be discontinued in 2024 due to the extensive costs and resources required to comply with new regulatory standards. This reduction in the availability of approved tests limits the overall growth potential of the diagnostics sector.
Market Trends
The expansion of Syndromic Multiplex Diagnostic Panels is revolutionizing clinical management by facilitating the simultaneous detection of multiple pathogens from a single sample, thereby addressing the difficulty of distinguishing symptoms in respiratory and gastrointestinal infections. This methodology improves operational efficiency in healthcare facilities by replacing sequential testing with comprehensive panels that provide rapid, actionable results for co-circulating viruses. The market viability of this trend is highlighted by the strong performance of specialized syndromic platforms; according to bioM?rieux?s 'First-Half 2024 Results' in September 2024, sales of BIOFIRE respiratory panels rose by 17 percent in the second quarter, driven by the solution?s competitiveness and the utilization of the existing installed base.
In parallel, the acceleration of decentralized and Point-of-Care (POC) testing is reshaping the diagnostic landscape by moving complex molecular testing capabilities from reference laboratories to near-patient settings, such as urgent care clinics and physician offices. This shift is fueled by the need to shorten turnaround times for treatment initiation, enabling providers to make immediate clinical decisions without the logistical delays associated with central lab transport. Industry leaders are capitalizing on this demand by broadening their portfolios of compact, automated systems. According to Danaher?s 'Third Quarter 2024 Results' in October 2024, Cepheid?s diagnostics revenue for respiratory products reached $425 million for the quarter, underscoring the sustained market reliance on rapid, decentralized molecular testing solutions.
Key Market Players
%li%BioMerieux SA
%li%Bio-Rad Laboratories, Inc.
%li%Becton, Dickinson and Company
%li%Agilent Technologies, Inc.
%li%Abbott Laboratories, Inc.
%li%Thermo Fisher Scientific, Inc.
%li%Roche Diagnostics Corporation
%li%DiaSorin SpA
%li%F. Hoffmann-La Roche Ltd.
%li%Danaher Corporation
Report Scope
In this report, the Global Emerging Infectious Disease Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
%li%Emerging Infectious Disease Diagnostics Market, By Application
%li%%li%Laboratory Testing
%li%%li%Point of Care Testing
%li%Emerging Infectious Disease Diagnostics Market, By Technology
%li%%li%Polymerase chain reaction
%li%%li%Immunodiagnostics
%li%%li%Isothermal Nucleic Acid Amplification Technology (INAAT)
%li%%li%Next-Generation Sequencing (NGS)
%li%%li%Others
%li%Emerging Infectious Disease Diagnostics Market, By Type of Infection
%li%%li%Bacterial
%li%%li%Viral
%li%%li%Fungal
%li%%li%Others
%li%Emerging Infectious Disease Diagnostics Market, By Disease Type
%li%%li%Respiratory Infections
%li%%li%Gastrointestinal Infections
%li%%li%Sexually Transmitted Infections (STIs)
%li%%li%Others
%li%Emerging Infectious Disease Diagnostics Market, By End user
%li%%li%Hospitals & Clinics
%li%%li%Diagnostic laboratories
%li%%li%Others
%li%Emerging Infectious Disease Diagnostics Market, By Region
%li%%li%North America
%li%%li%%li%United States
%li%%li%%li%Canada
%li%%li%%li%Mexico
%li%%li%Europe
%li%%li%%li%France
%li%%li%%li%United Kingdom
%li%%li%%li%Italy
%li%%li%%li%Germany
%li%%li%%li%Spain
%li%%li%Asia Pacific
%li%%li%%li%China
%li%%li%%li%India
%li%%li%%li%Japan
%li%%li%%li%Australia
%li%%li%%li%South Korea
%li%%li%South America
%li%%li%%li%Brazil
%li%%li%%li%Argentina
%li%%li%%li%Colombia
%li%%li%Middle East & Africa
%li%%li%%li%South Africa
%li%%li%%li%Saudi Arabia
%li%%li%%li%UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Emerging Infectious Disease Diagnostics Market.
Available Customizations:
Global Emerging Infectious Disease Diagnostics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
%li%Detailed analysis and profiling of additional market players (up to five).
1. PRODUCT OVERVIEW
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. VOICE OF CUSTOMER
5. GLOBAL EMERGING INFECTIOUS DISEASE DIAGNOSTICS MARKET OUTLOOK
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Application (Laboratory Testing, Point of Care Testing)
5.2.2. By Technology (Polymerase chain reaction, Immunodiagnostics, Isothermal Nucleic Acid Amplification Technology (INAAT), Next-Generation Sequencing (NGS), Others)
5.2.3. By Type of Infection (Bacterial, Viral, Fungal, Others)
5.2.4. By Disease Type (Respiratory Infections, Gastrointestinal Infections, Sexually Transmitted Infections (STIs), Others)
5.2.5. By End user (Hospitals & Clinics, Diagnostic laboratories, Others)
5.2.6. By Region
5.2.7. By Company (2025)
5.3. Market Map
6. NORTH AMERICA EMERGING INFECTIOUS DISEASE DIAGNOSTICS MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Application
6.2.2. By Technology
6.2.3. By Type of Infection
6.2.4. By Disease Type
6.2.5. By End user
6.2.6. By Country
6.3. North America: Country Analysis
6.3.1. United States Emerging Infectious Disease Diagnostics Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Application
6.3.1.2.2. By Technology
6.3.1.2.3. By Type of Infection
6.3.1.2.4. By Disease Type
6.3.1.2.5. By End user
6.3.2. Canada Emerging Infectious Disease Diagnostics Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Application
6.3.2.2.2. By Technology
6.3.2.2.3. By Type of Infection
6.3.2.2.4. By Disease Type
6.3.2.2.5. By End user
6.3.3. Mexico Emerging Infectious Disease Diagnostics Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Application
6.3.3.2.2. By Technology
6.3.3.2.3. By Type of Infection
6.3.3.2.4. By Disease Type
6.3.3.2.5. By End user
7. EUROPE EMERGING INFECTIOUS DISEASE DIAGNOSTICS MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Application
7.2.2. By Technology
7.2.3. By Type of Infection
7.2.4. By Disease Type
7.2.5. By End user
7.2.6. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Emerging Infectious Disease Diagnostics Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Application
7.3.1.2.2. By Technology
7.3.1.2.3. By Type of Infection
7.3.1.2.4. By Disease Type
7.3.1.2.5. By End user
7.3.2. France Emerging Infectious Disease Diagnostics Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Application
7.3.2.2.2. By Technology
7.3.2.2.3. By Type of Infection
7.3.2.2.4. By Disease Type
7.3.2.2.5. By End user
7.3.3. United Kingdom Emerging Infectious Disease Diagnostics Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Application
7.3.3.2.2. By Technology
7.3.3.2.3. By Type of Infection
7.3.3.2.4. By Disease Type
7.3.3.2.5. By End user
7.3.4. Italy Emerging Infectious Disease Diagnostics Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Application
7.3.4.2.2. By Technology
7.3.4.2.3. By Type of Infection
7.3.4.2.4. By Disease Type
7.3.4.2.5. By End user
7.3.5. Spain Emerging Infectious Disease Diagnostics Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Application
7.3.5.2.2. By Technology
7.3.5.2.3. By Type of Infection
7.3.5.2.4. By Disease Type
7.3.5.2.5. By End user
8. ASIA PACIFIC EMERGING INFECTIOUS DISEASE DIAGNOSTICS MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Application
8.2.2. By Technology
8.2.3. By Type of Infection
8.2.4. By Disease Type
8.2.5. By End user
8.2.6. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Emerging Infectious Disease Diagnostics Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Application
8.3.1.2.2. By Technology
8.3.1.2.3. By Type of Infection
8.3.1.2.4. By Disease Type
8.3.1.2.5. By End user
8.3.2. India Emerging Infectious Disease Diagnostics Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Application
8.3.2.2.2. By Technology
8.3.2.2.3. By Type of Infection
8.3.2.2.4. By Disease Type
8.3.2.2.5. By End user
8.3.3. Japan Emerging Infectious Disease Diagnostics Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Application
8.3.3.2.2. By Technology
8.3.3.2.3. By Type of Infection
8.3.3.2.4. By Disease Type
8.3.3.2.5. By End user
8.3.4. South Korea Emerging Infectious Disease Diagnostics Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Application
8.3.4.2.2. By Technology
8.3.4.2.3. By Type of Infection
8.3.4.2.4. By Disease Type
8.3.4.2.5. By End user
8.3.5. Australia Emerging Infectious Disease Diagnostics Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Application
8.3.5.2.2. By Technology
8.3.5.2.3. By Type of Infection
8.3.5.2.4. By Disease Type
8.3.5.2.5. By End user
9. MIDDLE EAST & AFRICA EMERGING INFECTIOUS DISEASE DIAGNOSTICS MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Application
9.2.2. By Technology
9.2.3. By Type of Infection
9.2.4. By Disease Type
9.2.5. By End user
9.2.6. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia Emerging Infectious Disease Diagnostics Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Application
9.3.1.2.2. By Technology
9.3.1.2.3. By Type of Infection
9.3.1.2.4. By Disease Type
9.3.1.2.5. By End user
9.3.2. UAE Emerging Infectious Disease Diagnostics Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Application
9.3.2.2.2. By Technology
9.3.2.2.3. By Type of Infection
9.3.2.2.4. By Disease Type
9.3.2.2.5. By End user
9.3.3. South Africa Emerging Infectious Disease Diagnostics Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Application
9.3.3.2.2. By Technology
9.3.3.2.3. By Type of Infection
9.3.3.2.4. By Disease Type
9.3.3.2.5. By End user
10. SOUTH AMERICA EMERGING INFECTIOUS DISEASE DIAGNOSTICS MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Application
10.2.2. By Technology
10.2.3. By Type of Infection
10.2.4. By Disease Type
10.2.5. By End user
10.2.6. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Emerging Infectious Disease Diagnostics Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Application
10.3.1.2.2. By Technology
10.3.1.2.3. By Type of Infection
10.3.1.2.4. By Disease Type
10.3.1.2.5. By End user
10.3.2. Colombia Emerging Infectious Disease Diagnostics Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Application
10.3.2.2.2. By Technology
10.3.2.2.3. By Type of Infection
10.3.2.2.4. By Disease Type
10.3.2.2.5. By End user
10.3.3. Argentina Emerging Infectious Disease Diagnostics Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Application
10.3.3.2.2. By Technology
10.3.3.2.3. By Type of Infection
10.3.3.2.4. By Disease Type
10.3.3.2.5. By End user
11. MARKET DYNAMICS
11.1. Drivers
11.2. Challenges
12. MARKET TRENDS & DEVELOPMENTS
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. GLOBAL EMERGING INFECTIOUS DISEASE DIAGNOSTICS MARKET: SWOT ANALYSIS
14. PORTER'S FIVE FORCES ANALYSIS
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products
15. COMPETITIVE LANDSCAPE
15.1. BioMerieux SA
15.1.1. Business Overview
15.1.2. Products & Services
15.1.3. Recent Developments
15.1.4. Key Personnel
15.1.5. SWOT Analysis
15.2. Bio-Rad Laboratories, Inc.
15.3. Becton, Dickinson and Company
15.4. Agilent Technologies, Inc.
15.5. Abbott Laboratories, Inc.
15.6. Thermo Fisher Scientific, Inc.
15.7. Roche Diagnostics Corporation
15.8. DiaSorin SpA
15.9. F. Hoffmann-La Roche Ltd.
15.10. Danaher Corporation
16. STRATEGIC RECOMMENDATIONS
17. ABOUT US & DISCLAIMER
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. VOICE OF CUSTOMER
5. GLOBAL EMERGING INFECTIOUS DISEASE DIAGNOSTICS MARKET OUTLOOK
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Application (Laboratory Testing, Point of Care Testing)
5.2.2. By Technology (Polymerase chain reaction, Immunodiagnostics, Isothermal Nucleic Acid Amplification Technology (INAAT), Next-Generation Sequencing (NGS), Others)
5.2.3. By Type of Infection (Bacterial, Viral, Fungal, Others)
5.2.4. By Disease Type (Respiratory Infections, Gastrointestinal Infections, Sexually Transmitted Infections (STIs), Others)
5.2.5. By End user (Hospitals & Clinics, Diagnostic laboratories, Others)
5.2.6. By Region
5.2.7. By Company (2025)
5.3. Market Map
6. NORTH AMERICA EMERGING INFECTIOUS DISEASE DIAGNOSTICS MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Application
6.2.2. By Technology
6.2.3. By Type of Infection
6.2.4. By Disease Type
6.2.5. By End user
6.2.6. By Country
6.3. North America: Country Analysis
6.3.1. United States Emerging Infectious Disease Diagnostics Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Application
6.3.1.2.2. By Technology
6.3.1.2.3. By Type of Infection
6.3.1.2.4. By Disease Type
6.3.1.2.5. By End user
6.3.2. Canada Emerging Infectious Disease Diagnostics Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Application
6.3.2.2.2. By Technology
6.3.2.2.3. By Type of Infection
6.3.2.2.4. By Disease Type
6.3.2.2.5. By End user
6.3.3. Mexico Emerging Infectious Disease Diagnostics Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Application
6.3.3.2.2. By Technology
6.3.3.2.3. By Type of Infection
6.3.3.2.4. By Disease Type
6.3.3.2.5. By End user
7. EUROPE EMERGING INFECTIOUS DISEASE DIAGNOSTICS MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Application
7.2.2. By Technology
7.2.3. By Type of Infection
7.2.4. By Disease Type
7.2.5. By End user
7.2.6. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Emerging Infectious Disease Diagnostics Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Application
7.3.1.2.2. By Technology
7.3.1.2.3. By Type of Infection
7.3.1.2.4. By Disease Type
7.3.1.2.5. By End user
7.3.2. France Emerging Infectious Disease Diagnostics Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Application
7.3.2.2.2. By Technology
7.3.2.2.3. By Type of Infection
7.3.2.2.4. By Disease Type
7.3.2.2.5. By End user
7.3.3. United Kingdom Emerging Infectious Disease Diagnostics Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Application
7.3.3.2.2. By Technology
7.3.3.2.3. By Type of Infection
7.3.3.2.4. By Disease Type
7.3.3.2.5. By End user
7.3.4. Italy Emerging Infectious Disease Diagnostics Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Application
7.3.4.2.2. By Technology
7.3.4.2.3. By Type of Infection
7.3.4.2.4. By Disease Type
7.3.4.2.5. By End user
7.3.5. Spain Emerging Infectious Disease Diagnostics Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Application
7.3.5.2.2. By Technology
7.3.5.2.3. By Type of Infection
7.3.5.2.4. By Disease Type
7.3.5.2.5. By End user
8. ASIA PACIFIC EMERGING INFECTIOUS DISEASE DIAGNOSTICS MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Application
8.2.2. By Technology
8.2.3. By Type of Infection
8.2.4. By Disease Type
8.2.5. By End user
8.2.6. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Emerging Infectious Disease Diagnostics Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Application
8.3.1.2.2. By Technology
8.3.1.2.3. By Type of Infection
8.3.1.2.4. By Disease Type
8.3.1.2.5. By End user
8.3.2. India Emerging Infectious Disease Diagnostics Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Application
8.3.2.2.2. By Technology
8.3.2.2.3. By Type of Infection
8.3.2.2.4. By Disease Type
8.3.2.2.5. By End user
8.3.3. Japan Emerging Infectious Disease Diagnostics Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Application
8.3.3.2.2. By Technology
8.3.3.2.3. By Type of Infection
8.3.3.2.4. By Disease Type
8.3.3.2.5. By End user
8.3.4. South Korea Emerging Infectious Disease Diagnostics Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Application
8.3.4.2.2. By Technology
8.3.4.2.3. By Type of Infection
8.3.4.2.4. By Disease Type
8.3.4.2.5. By End user
8.3.5. Australia Emerging Infectious Disease Diagnostics Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Application
8.3.5.2.2. By Technology
8.3.5.2.3. By Type of Infection
8.3.5.2.4. By Disease Type
8.3.5.2.5. By End user
9. MIDDLE EAST & AFRICA EMERGING INFECTIOUS DISEASE DIAGNOSTICS MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Application
9.2.2. By Technology
9.2.3. By Type of Infection
9.2.4. By Disease Type
9.2.5. By End user
9.2.6. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia Emerging Infectious Disease Diagnostics Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Application
9.3.1.2.2. By Technology
9.3.1.2.3. By Type of Infection
9.3.1.2.4. By Disease Type
9.3.1.2.5. By End user
9.3.2. UAE Emerging Infectious Disease Diagnostics Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Application
9.3.2.2.2. By Technology
9.3.2.2.3. By Type of Infection
9.3.2.2.4. By Disease Type
9.3.2.2.5. By End user
9.3.3. South Africa Emerging Infectious Disease Diagnostics Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Application
9.3.3.2.2. By Technology
9.3.3.2.3. By Type of Infection
9.3.3.2.4. By Disease Type
9.3.3.2.5. By End user
10. SOUTH AMERICA EMERGING INFECTIOUS DISEASE DIAGNOSTICS MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Application
10.2.2. By Technology
10.2.3. By Type of Infection
10.2.4. By Disease Type
10.2.5. By End user
10.2.6. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Emerging Infectious Disease Diagnostics Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Application
10.3.1.2.2. By Technology
10.3.1.2.3. By Type of Infection
10.3.1.2.4. By Disease Type
10.3.1.2.5. By End user
10.3.2. Colombia Emerging Infectious Disease Diagnostics Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Application
10.3.2.2.2. By Technology
10.3.2.2.3. By Type of Infection
10.3.2.2.4. By Disease Type
10.3.2.2.5. By End user
10.3.3. Argentina Emerging Infectious Disease Diagnostics Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Application
10.3.3.2.2. By Technology
10.3.3.2.3. By Type of Infection
10.3.3.2.4. By Disease Type
10.3.3.2.5. By End user
11. MARKET DYNAMICS
11.1. Drivers
11.2. Challenges
12. MARKET TRENDS & DEVELOPMENTS
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. GLOBAL EMERGING INFECTIOUS DISEASE DIAGNOSTICS MARKET: SWOT ANALYSIS
14. PORTER'S FIVE FORCES ANALYSIS
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products
15. COMPETITIVE LANDSCAPE
15.1. BioMerieux SA
15.1.1. Business Overview
15.1.2. Products & Services
15.1.3. Recent Developments
15.1.4. Key Personnel
15.1.5. SWOT Analysis
15.2. Bio-Rad Laboratories, Inc.
15.3. Becton, Dickinson and Company
15.4. Agilent Technologies, Inc.
15.5. Abbott Laboratories, Inc.
15.6. Thermo Fisher Scientific, Inc.
15.7. Roche Diagnostics Corporation
15.8. DiaSorin SpA
15.9. F. Hoffmann-La Roche Ltd.
15.10. Danaher Corporation
16. STRATEGIC RECOMMENDATIONS
17. ABOUT US & DISCLAIMER
